A Study Of PF-06647263 In Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2017-05-10
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available

• Performance Status of 0 or 1

• Adequate bone marrow, kidney, and liver function

• Part 2 includes advanced triple negative breast cancer patients.

Exclusion Criteria:

• Brain metastases requiring steroids

• Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start

• Active and clinically significant bacterial, fungal or viral infection